579 related articles for article (PubMed ID: 27655102)
21. Methylation of TNFRSF13B and TNFRSF13C in duodenal mucosa in canine inflammatory bowel disease and its association with decreased mucosal IgA expression.
Maeda S; Ohno K; Fujiwara-Igarashi A; Tomiyasu H; Fujino Y; Tsujimoto H
Vet Immunol Immunopathol; 2014 Jul; 160(1-2):97-106. PubMed ID: 24814046
[TBL] [Abstract][Full Text] [Related]
22. Similarities and differences between selective and nonselective BAFF blockade in murine SLE.
Ramanujam M; Wang X; Huang W; Liu Z; Schiffer L; Tao H; Frank D; Rice J; Diamond B; Yu KO; Porcelli S; Davidson A
J Clin Invest; 2006 Mar; 116(3):724-34. PubMed ID: 16485042
[TBL] [Abstract][Full Text] [Related]
23. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
24. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
25. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
26. Travelling with the BAFF/BLyS family: are we there yet?
Mackay F; Cancro MP
Semin Immunol; 2006 Oct; 18(5):261-2. PubMed ID: 16905331
[No Abstract] [Full Text] [Related]
27. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD.
Liu H; Dasgupta S; Fu Y; Bailey B; Roy C; Lightcap E; Faustin B
BMC Immunol; 2019 Nov; 20(1):42. PubMed ID: 31718550
[TBL] [Abstract][Full Text] [Related]
28. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
29. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review.
Lied GA; Berstad A
Scand J Immunol; 2011 Jan; 73(1):1-7. PubMed ID: 21128997
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
Jasek M; Wagner M; Sobczynski M; Wolowiec D; Kuliczkowski K; Woszczyk D; Kielbinski M; Kusnierczyk P; Frydecka I; Karabon L
Tissue Antigens; 2015 Oct; 86(4):279-84. PubMed ID: 26268376
[TBL] [Abstract][Full Text] [Related]
31. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde S; Kristoffersen EK; Sapkota D; Risa K; Dahl O; Bruland O; Mella O; Fluge Ø
PLoS One; 2016; 11(8):e0161226. PubMed ID: 27536947
[TBL] [Abstract][Full Text] [Related]
32. Belimumab therapy in systemic lupus erythematosus.
Zouali M; Uy EA
BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
[TBL] [Abstract][Full Text] [Related]
33. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
[TBL] [Abstract][Full Text] [Related]
34. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
Vincent FB; Morand EF; Mackay F
Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
[TBL] [Abstract][Full Text] [Related]
35. TACI and BAFF-R mediate isotype switching in B cells.
Castigli E; Wilson SA; Scott S; Dedeoglu F; Xu S; Lam KP; Bram RJ; Jabara H; Geha RS
J Exp Med; 2005 Jan; 201(1):35-9. PubMed ID: 15630136
[TBL] [Abstract][Full Text] [Related]
36. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
37. Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation.
Jackson SW; Scharping NE; Jacobs HM; Wang S; Chait A; Rawlings DJ
J Immunol; 2016 Dec; 197(12):4529-4534. PubMed ID: 27837104
[TBL] [Abstract][Full Text] [Related]
38. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
39. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
[TBL] [Abstract][Full Text] [Related]
40. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.
Lin WY; Gong Q; Seshasayee D; Lin Z; Ou Q; Ye S; Suto E; Shu J; Lee WP; Lee CW; Fuh G; Leabman M; Iyer S; Howell K; Gelzleichter T; Beyer J; Danilenko D; Yeh S; DeForge LE; Ebens A; Thompson JS; Ambrose C; Balazs M; Starovasnik MA; Martin F
Blood; 2007 Dec; 110(12):3959-67. PubMed ID: 17687108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
